Dosing & Uses
Dosage Forms & Strengths
powder for injection
Administer ASAP (within 30 minutes) after onset of acute MI
30-50 mg IV bolus over 5 sec once (based on weight)
- <60 kg: 30 mg
- 60-70 kg: 35 mg
- 70-80 kg: 40 mg
- 80-90 kg: 45 mg
- >90 kg: 50 mg
Restore Function to Hemodialysis Catheters (Orphan)
Indicated to estore function to hemodialysis catheters
Orphan indication sponsor
- Genentech, Inc; 1 DNA Way; South San Francisco, CA 94080-4990
Safety & efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Minor bleeding (22%)
Frequency Not Defined
Active bleeding, history of CVA, recent (within 2 months) intracranial or intraspinal surgery or trauma, intracranial neoplasm, AVM, aneurysm, bleeding diathesis, severe uncontrolled HTN, recent (within 3 mth) facial trauma, suspected aortic dissection
See thrombolytic indications/contraindications
Recent major surgery, cerebrovascular disease, recent GI or GU bleeding, HTN, acute pericarditis, subacute endocarditis, hemostatic defects, high likelihood of left heart thrombus, severe thrombophlebitis, severe hepatic/renal dysfunction, currently receiving oral anticoagulants, diabetic hemorrhagic retinopathy, elderly, recent admin of GP IIb/IIIa inhibitors
Acute pericarditis, subacute endocarditis
Ischemic Stroke: may have no benefit if used after 3 hr of onset
Current use of warfarin and INR in high range may increase bleeding risk
Monitor potential bleeding sites
Cholesterol embolism reported
Pregnancy or breastfeeding
Adjuncts for MI treatment
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known whether drug crosses into breast milk, nursing not a priority in AMI
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Genetically engineered variant of alteplase with multiple point mutations of tPA molecule resulting in longer plasma half-life, enhanced fibrin specificity, & increased resistance to inactivation by plasminogen activator inhibitor 1 (PAI-1) compared to alteplase
Promotes thrombolysis by converting plasminogen to plasmin which degrades fibrin & fibrinogen
Half-Life: 90-130 min
Onset: 30 min
Metabolites: Degradation products (constituent amino acids of tenecteplase)
Total Body Clearance: 99-119 mL/min
Add 10 mL SWI to a 50 mg vial using TwinPak® device directing stream of diluent into powder. If foaming (usually slight) occurs, leave vial undisturbed for several minutes to allow dissipation of any large bubbles. Gently swirl (do not shake) until contents are completely dissolved.
Do not discard shield assembly
Use immediately or may be refrigerated up to 8 hr
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.